Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more
Terminated No phase listed Observational Accepts healthy volunteers

Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

NCT05672875
Conditions
Anthrax
Interventions
Anthrax LF Dx System
Diagnostic Test
Lead sponsor
SRI International
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Dayton, Ohio
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VELOCITY: An Anthrax Vaccine Clinical Study

NCT03877926
Conditions
Anthrax
Interventions
AV7909, BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 31 more
Terminated Phase 2 Interventional Accepts healthy volunteers

UMD rPA Regimen Trial in Adults

NCT00133484
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Anthrax vaccine absorbed made from Bacillus anthracis (AVA), Recombinant protein antigen (rPA) made from Bacillus anthrax, Recombinant protein antigen (rPA) made from Escherichia coli
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

NCT04067011
Conditions
Anthrax
Interventions
Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909
Drug · Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
DeLand, Florida • Kansas City, Missouri • Omaha, Nebraska + 1 more
Conditions
Febrile Infection, Anthrax
Interventions
TaqMan Bacillus anthracis Detection Kit
Device
Lead sponsor
MRI Global
Industry
Eligibility
2 Years to 89 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Tarpon Springs, Florida • Fall River, Massachusetts • Franklin, Massachusetts
Conditions
Bacillus Anthracis (Anthrax)
Interventions
AVA, rPA vaccine containing alhydrogel
Biological
Lead sponsor
PharmAthene UK Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
16
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers

Monoclonal Antibody for Treatment of Inhalation Anthrax

NCT00138411
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Ciprofloxacin 500 mg, ETI-204 (Anthim)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

NCT01263691
Conditions
Bacillus Anthracis (Anthrax) Infection
Interventions
BioThrax, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3, AV7909 Formulation 4, Control
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 50 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Miami, Florida • Raleigh, North Carolina • Salt Lake City, Utah
Conditions
Anthrax
Interventions
Recombinant Protective Antigen, Anthrax Vaccine Adsorbed
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Timeline
2003 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland